PrescribedReta

SHEET 006 — Sources

Retatrutide references.

Every source cited across this site — numbered, with DOI and PubMed link where available.

Retatrutide references

All citations used across this site are listed below, numbered to match inline citations [1]–[15]. DOIs and PubMed/PMC URLs are provided for every entry where available.

  1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. ↗
  2. Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529-544. ↗
  3. Li W, Zhou Q, Cong Z, et al. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery. 2024;10:77. ↗
  4. Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400:1869-1881. ↗
  5. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30:2037-2048. ↗
  6. Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide-A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15:796. ↗
  7. Eli Lilly and Company. The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Function. ClinicalTrials.gov. 2024. NCT06383390. ↗
  8. Bailey CJ, et al. Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities. Peptides. 2025;187:171380. ↗
  9. Kokkorakis M, et al. Emerging pharmacotherapies for obesity: A systematic review. Pharmacological Reviews. 2025;77(1):100002. ↗
  10. The First Triple Agonist for Antiobesity: Retatrutide. Clin Diabetes. 2024. ↗
  11. The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes or Overweight/Obesity. Kidney Int Rep. 2025. ↗
  12. Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide. Nephrol Dial Transplant. 2025. ↗
  13. Pillai AA, et al. Triple Hormone Receptor Agonism: The Role of Retatrutide in Addressing Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Comprehensive Review. Cardiology in Review. 2026. ↗
  14. Pallavi K, et al. Efficacy and Safety of Retatrutide in the Treatment of Diabetes and/or Obesity Comorbid with Chronic Kidney disease: a Systematic Review and Meta-Analysis. Maedica. 2025. ↗
  15. Appetite, eating attitudes, and eating behaviours during treatment with retatrutide. Diabetes Obes Metab. 2025. ↗